Status:

COMPLETED

Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases

Lead Sponsor:

Juergen Debus

Collaborating Sponsors:

Heidelberg University

Conditions:

SCLC

Brain Metastases

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Patients suffering from small cell lung cancer (SCLC) are at high risk for developing brain metastases (BM). To prevent a clinical manifestation of preexisting microscopic brain dissemination, prophyl...

Detailed Description

Scientific Background: Patients suffering from BM from SCLC have a poor prognosis with a median survival ranging between 2-14 months. Treatment options for BM in SCLC are usually limited to WBRT, ster...

Eligibility Criteria

Inclusion

  • histologically confirmed small cell lung cancer (SCLC)
  • Magentic resonance (MR)-imaging confirmed cerebral metastases (no resection, max. number of 10)
  • age ≥ 18 years of Age
  • For women with childbearing potential, (and men) adequate contraception.
  • Ability of subject to understand character and individual consequences of the clinical trial
  • Written informed consent (must be available before enrolment in the trial)

Exclusion

  • refusal of the patients to take part in the study
  • previous radiotherapy of the brain
  • Patients who have not yet recovered from acute high-grade toxicities of prior therapies
  • Known carcinoma \< 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy
  • Pregnant or lactating women
  • Participation in another competing clinical study or observation period of competing trials, respectively
  • MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants)
  • Karnofsky score (KPS) \<60
  • Simultaneous cytotoxic chemotherapy
  • Last application of chemotherapy/immunotherapy/targeted therapy \<1 week before cerebral radiotherapy

Key Trial Info

Start Date :

December 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2023

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT03297788

Start Date

December 1 2017

End Date

December 1 2023

Last Update

January 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital of Heidelberg, Department of Radiation Oncology

Heidelberg, Germany, 69120